Muscle preservation on GLP-1s

The concern

Any rapid weight loss — whether caused by a GLP-1, a very-low-calorie diet, or bariatric surgery — is accompanied by loss of fat-free mass (FFM) alongside fat mass. FFM includes skeletal muscle, organ mass, and bone. The open question with GLP-1s is whether the proportion of weight lost as lean mass is larger, smaller, or similar to other forms of rapid weight loss.

What the DEXA substudies show

The STEP 1 DEXA substudy (Wilding et al., NEJM 2021, body composition appendix) reported that in participants receiving semaglutide 2.4 mg, roughly 39% of total mass lost was lean mass and roughly 61% was fat mass. That proportion is broadly consistent with historical data from caloric restriction in non-exercising adults: sedentary weight loss of any kind typically partitions 20–40% as lean mass.

In SURMOUNT-1 (tirzepatide, Jastreboff et al., NEJM 2022), a DEXA substudy reported fat mass reductions of roughly 3× the lean mass reductions, yielding a somewhat better ratio than the STEP 1 substudy, though direct comparison is limited by differing methodologies and participant populations.

The important caveat: trial participants were not typically following structured resistance training programs. Real-world outcomes in people who lift and eat adequate protein look different.

What can mitigate lean mass loss

Evidence on muscle preservation during weight loss is primarily from the non-GLP-1 literature, but mechanistic reasoning and a few post-hoc analyses suggest two levers matter most:

1. Adequate protein intake. Meta-analyses in caloric deficit (Helms et al., 2014; Longland et al., 2016) point to targets of roughly 1.6–2.4 g/kg bodyweight/day for resistance-trained individuals in a deficit.
2. Progressive resistance training. Resistance training during caloric restriction reduces FFM loss substantially — sometimes by more than half — vs. caloric restriction alone.

Note what's missing: there is no published RCT specifically testing "GLP-1 + resistance training + high protein" vs. "GLP-1 alone." This is a gap that several academic groups are attempting to close; until results are published, the best-supported inference is that the general principles of preserving lean mass in a deficit likely apply on GLP-1s as well.

What the research does not show

Claims that GLP-1s specifically and disproportionately cause muscle loss beyond what would be expected from the magnitude of weight loss are not well-supported. The weight-loss magnitude with these drugs is simply larger than most people have experienced before, so the absolute (not relative) lean mass loss is larger too.

Bottom line

People losing ~15% of bodyweight on a GLP-1 should expect meaningful lean mass loss — measurable on DEXA. Evidence supports protein at roughly 1.6–2.4 g/kg/day and consistent resistance training as the primary mitigations. Clinicians also monitor grip strength, lean mass, and functional capacity in older patients where sarcopenia risk is highest.